Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (271-280 of 279) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 279 results.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Nature Medicine|June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialIrene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Nature Medicine|January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trialLotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
Science (New York, N.Y.)|May 30, 2020
The human tumor microbiome is composed of tumor type-specific intracellular bacteriaDeborah Nejman, Ilana Livyatan, Garold Fuks, et al.
Nature Medicine|October 8, 2025
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trialSabine E Breukers, Joleen J H Traets, Stan W van Dijk, et al.
Nature|January 17, 2020
B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.
The New England Journal of Medicine|December 8, 2022
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced MelanomaMaartje W Rohaan, Troels H Borch, Joost H van den Berg, et al.
The New England Journal of Medicine|June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaChristian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Pageof 28

Showing results (271-280 of 279) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 279 results.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Nature Medicine|June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialIrene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Nature Medicine|January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trialLotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
Science (New York, N.Y.)|May 30, 2020
The human tumor microbiome is composed of tumor type-specific intracellular bacteriaDeborah Nejman, Ilana Livyatan, Garold Fuks, et al.
Nature Medicine|October 8, 2025
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trialSabine E Breukers, Joleen J H Traets, Stan W van Dijk, et al.
Nature|January 17, 2020
B cells and tertiary lymphoid structures promote immunotherapy responseBeth A Helmink, Sangeetha M Reddy, Jianjun Gao, et al.
The New England Journal of Medicine|December 8, 2022
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced MelanomaMaartje W Rohaan, Troels H Borch, Joost H van den Berg, et al.
The New England Journal of Medicine|June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaChristian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Pageof 28